Loading…
← CockpitCompetitor Analysis › PHIL.MI Philogen SpAOpen in the cockpit ↗

Philogen SpAPHIL.MICompetitor analysis, valuation and peers

Italy · EUR·Health Care›Pharmaceuticals: Major
Momentum weak 21
Mkt cap
$672M
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$262,831
20-day average traded
Fwd P/E
10.1×
forward earnings
ROIC−WACC
n/a
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · EUR€20.95
1D+0.2%
1W-0.2%
1M-3.2%
3M-10.7%
6M-10.8%
YTD-10.1%
1Y-10.1%
ATR %2.9%
52w lowhigh19.4% off high

What Philogen does

Employees: 214

Philogen at a glance

Size Philogen (PHIL.MI) is an Italy Health Care company (Pharmaceuticals: Major) with a market value of $672M, the 95th largest of 121 Italy companies the cockpit tracks. Shares closed at €20.95 on 18 Nov 2026.

Performance Over six months the shares fell 10.8%, against -6.0% for the median peer and +3.1% for the Italy market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 294.9% over the last twelve months (peer median +10.2%); the operating margin is 78.8% (peer median 9.7%).

Valuation It trades at 10.1× forward earnings against a peer median of 21.5× (2nd cheapest of 9).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 94PHIL.MI 90
Six months, rebased to 100: Philogen against the median of its 20 peers (local-currency closes).

Philogen financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€311M€314M€74.0M€23.1M€23.7M
Revenue growth—+325%+220%-2%—
Gross profit€263M€272M€39.5M-€6.36M€914,000
EBITDA€250M€256M€38.0M-€7.19M-€561,000
Net income€225M€230M€45.3M-€6.16M-€5.38M
Free cash flow€268M€268M€40.4M-€8.80M-€8.58M
Capital expenditure€2.20M€3.63M€2.41M€5.86M€4.21M
Total debtn/a€10.9M€11.5M€14.9M€15.8M

Quarterly statements and history in the cockpit →

Philogen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%688488ANNX688658600351SPARC0009154985FDCNVCTINNOVACAP600829000566300016412345343008780570ABUSSGMTPHIL.MI6-month return →1-month return →
Up and to the right = strong over both horizons. Philogen is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%50×100×6884886886580009154985INNOVACAP3000164534603998PHIL.MIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Philogen is the large dot.

Philogen competitors and peer comparison

How Philogen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Philogen against its 20 peers (data as of 18 Nov 2026)
MeasurePHIL.MIPeer medianRank in peer set
1-month return-3.2%-3.7%11th highest of 21
6-month return-10.8%-6.0%10th lowest of 21
Distance from 52-week high-19.4%-32.5%6th highest of 21
Revenue growth (TTM)+294.9%+10.2%3rd highest of 18
Operating margin78.8%9.7%3rd highest of 18
Forward P/E10.1×21.5×2nd cheapest of 9
EV / EBITDA1.1×7.2×cheapest of 9
Net debt / EBITDA-1.3×-1.3×5th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a

Questions

Which companies are Philogen's closest peers?
The cockpit's peer set: Jiangsu Aidea Pharmaceutical (688488.SS), Annexon (ANNX), Youcare Pharmaceutical (688658.SS), Yabao Pharmaceutical (600351.SS), Sun Pharma Advanced Research (SPARC.NS), Shandong Wit Dyne Health (000915.SZ), Earth (4985.T), FDC (FDC.NS).
Is Philogen expensive compared with its peers?
On forward p/e it trades at 10.1× against a peer median of 21.5×, 2nd cheapest of 9 in its peer set.
How has Philogen stock performed?
Over six months to 18 Nov 2026 the shares returned -10.8% against -6.0% for the median peer; over one year -10.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.